GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Cyclically Adjusted PB Ratio

Glaukos (Glaukos) Cyclically Adjusted PB Ratio : 11.68 (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Glaukos's current share price is $99.48. Glaukos's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $8.52. Glaukos's Cyclically Adjusted PB Ratio for today is 11.68.

The historical rank and industry rank for Glaukos's Cyclically Adjusted PB Ratio or its related term are showing as below:

GKOS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.7   Med: 10.36   Max: 11.75
Current: 11.75

During the past years, Glaukos's highest Cyclically Adjusted PB Ratio was 11.75. The lowest was 7.70. And the median was 10.36.

GKOS's Cyclically Adjusted PB Ratio is ranked worse than
93.2% of 456 companies
in the Medical Devices & Instruments industry
Industry Median: 2.11 vs GKOS: 11.75

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Glaukos's adjusted book value per share data for the three months ended in Dec. 2023 was $9.401. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.52 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Glaukos Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Glaukos's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Cyclically Adjusted PB Ratio Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 9.33

Glaukos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 9.57 9.33

Competitive Comparison of Glaukos's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, Glaukos's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Cyclically Adjusted PB Ratio falls into.



Glaukos Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Glaukos's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=99.48/8.52
=11.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Glaukos's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=9.401/129.4194*129.4194
=9.401

Current CPI (Dec. 2023) = 129.4194.

Glaukos Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -5.093 99.070 -6.653
201503 0.207 99.621 0.269
201506 2.967 100.684 3.814
201509 2.952 100.392 3.806
201512 2.958 99.792 3.836
201603 3.029 100.470 3.902
201606 3.194 101.688 4.065
201609 3.309 101.861 4.204
201612 3.455 101.863 4.390
201703 3.587 102.862 4.513
201706 3.657 103.349 4.579
201709 3.823 104.136 4.751
201712 3.992 104.011 4.967
201803 4.107 105.290 5.048
201806 4.227 106.317 5.146
201809 4.543 106.507 5.520
201812 4.815 105.998 5.879
201903 5.105 107.251 6.160
201906 5.126 108.070 6.139
201909 5.150 108.329 6.153
201912 15.477 108.420 18.475
202003 14.545 108.902 17.285
202006 14.869 108.767 17.692
202009 14.758 109.815 17.393
202012 14.751 109.897 17.371
202103 12.825 111.754 14.852
202106 12.575 114.631 14.197
202109 12.825 115.734 14.342
202112 12.502 117.630 13.755
202203 12.690 121.301 13.539
202206 11.862 125.017 12.280
202209 11.509 125.227 11.894
202212 11.099 125.222 11.471
202303 10.607 127.348 10.780
202306 10.103 128.729 10.157
202309 9.804 129.860 9.771
202312 9.401 129.419 9.401

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glaukos  (NYSE:GKOS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Glaukos Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Glaukos's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022